hinokiresinol

RN given for (S-(E))-isomer; inhibits binding of leukotriene B4 to neutrophils; structurein first source

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 04/01/2013 - "Similarly, in rats subjected to transient middle cerebral artery occlusion (1.5 h) followed by 24-h reperfusion, pre-ischemic treatment with trans-hinokiresinol, but not with cis-isomer, reduced cerebral infarct volume. "
2.	Ischemia 04/01/2013 - "When administered after onset of ischemia, trans-hinokiresinol, but not its cis-isomer reduced nitrotyrosine immunoreactivity in ischemic regions. "
3.	Cerebral Infarction 04/01/2013 - "Similarly, in rats subjected to transient middle cerebral artery occlusion (1.5 h) followed by 24-h reperfusion, pre-ischemic treatment with trans-hinokiresinol, but not with cis-isomer, reduced cerebral infarct volume. "
4.	Breast Neoplasms (Breast Cancer) 03/01/2000 - "Furthermore, cis- and trans-hinokiresinol stimulated the proliferation of estrogen-dependent T47D breast cancer cells, and their stimulatory effects were blocked by an estrogen antagonist, indicating that the compounds are estrogen agonists. "
5.	Anaphylaxis (Anaphylactic Shock) 11/01/2006 - "Orally and intraperitoneally administered hinokiresinol potently inhibited the passive anaphylaxis reaction in mice induced by IgE."